CD8+ tumor-specific Tc cells primed in vivo or in vitro against the BALB/c plasmacytoma ADJ-PC-5 use the same TcR V beta families but display distinct TC1 or TC2 characteristics.

[1]  C. Becker,et al.  Suppression of Tumour‐Specific Cytotoxic T‐Cell Responses Against the Syngeneic BALB/c Plasmacytoma ADJ‐PC‐5 by Tumour‐Induced CD8+ Regulatory T Cells Via IFN‐γ , 1996, Scandinavian journal of immunology.

[2]  M. Ruzek,et al.  Specific decrease of Th1-like activity in mice with plasma cell tumors. , 1995, International immunology.

[3]  T. Mosmann,et al.  Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. , 1995, Immunity.

[4]  D. Alarcón-Segovia,et al.  Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus , 1995, The Journal of experimental medicine.

[5]  F. Erard,et al.  Non-cytotoxic, IL-4, IL-5, IL-10 producing CD8+ T cells: their activation and effector functions. , 1994, Current opinion in immunology.

[6]  B. Sander,et al.  Similar frequencies and kinetics of cytokine producing cells in murine peripheral blood and spleen. Cytokine detection by immunoassay and intracellular immunostaining. , 1993, Journal of immunological methods.

[7]  C. Heusser,et al.  Detection of intracellular cytokines by flow cytometry. , 1993, Journal of immunological methods.

[8]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[9]  P. Altevogt,et al.  Murine Fcγ receptor proteins: identification of a previously unrecognized molecule with a monoclonal antibody (12‐15) , 1988 .

[10]  W. Paul,et al.  Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1 , 1985, Nature.

[11]  F. Takei.  Inhibition of mixed lymphocyte response by a rat monoclonal antibody to a novel murine lymphocyte activation antigen (MALA-2). , 1985, Journal of immunology.

[12]  H. Waldmann,et al.  Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo , 1984, Nature.

[13]  P. Brouckaert,et al.  Nitrite protects against morbidity and mortality associated with TNF- or LPS-induced shock in a soluble guanylate cyclase–dependent manner , 2009, The Journal of experimental medicine.

[14]  D. Sachs,et al.  Serologic cross-reactivity between Class I MHC molecules and an H-2- linked differentiation antigen as detected by monoclonal antibodies , 1984, The Journal of experimental medicine.

[15]  M. Loken,et al.  Flow cytometry as an analytical and preparative tool in immunology. , 1982, Journal of immunological methods.

[16]  K. Ozato,et al.  Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens. , 1980, Journal of immunology.

[17]  G. Galfré,et al.  Mac‐1: a macrophage differentiation antigen identified by monoclonal antibody , 1979, European journal of immunology.

[18]  J. Haimovich,et al.  Cell surface immunoglobulins of murine plasma cell tumors , 1977 .

[19]  V. Schirrmacher,et al.  Correlation of “sneaking through” of tumor cells with specific immunological impairment of the host , 1975, European journal of immunology.

[20]  L. Old,et al.  ANTIGENIC PROPERTIES OF CHEMICALLY INDUCED TUMORS * , 1962 .

[21]  D. Sulitzeanu.  Immunosuppressive factors in human cancer. , 1993, Advances in cancer research.

[22]  Walter F. Bodmer,et al.  MHC antigens and cancer: implications for T-cell surveillance. , 1992 .

[23]  R. Fernandez-Botran,et al.  Epitopes on CD45R [T200] molecules define differentiation antigens on murine B and T lymphocytes. , 1988, The Journal of molecular and cellular immunology : JMCI.

[24]  P. Marrack,et al.  The antigen-specific, major histocompatibility complex-restricted receptor on T cells. , 1986, Advances in immunology.

[25]  R. Zinkernagel,et al.  Cytotoxic T cell clone‐specific monoclonal antibodies used to select clonotypic antigen‐specific cytotoxic T cells , 1985, European journal of immunology.

[26]  R. North.  Down-regulation of the antitumor immune response. , 1985, Advances in cancer research.

[27]  D. Naor.  Suppressor cells: permitters and promoters of malignancy? , 1979, Advances in cancer research.